CAD is the primary underlying cause of AMI, and its inclusion as a comorbidity enables more accurate risk stratification while helping to contextualize the role of the homocysteine-to-albumin ratio (HAR) as a predictor of major adverse cardiovascular events (MACE). The gene discussed is ALB; the disease is coronary artery disorder.